Sheng Chen1,2,3, Wang Ni1, Xin-Zhen Yin1, Han-Qiu Liu4, Cong Lu3, Qiao-Juan Zheng3, Gui-Xian Zhao2, Yong-Feng Xu1, Lei Wu1, Liang Zhang1, Ning Wang3, Hong-Fu Li1, Zhi-Ying Wu1,5. 1. Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, The Collaborative Innovation Center for Brain Science, Zhejiang University School of Medicine, Hangzhou, China. 2. Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. 3. Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China. 4. Department of Radiology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. 5. Joint Institute for Genetics and Genome Medicine between Zhejiang University and University of Toronto, Zhejiang University, Hangzhou, China.
Abstract
AIM: To characterize clinical features and mutation spectrum in Chinese patients with CADASIL. METHODS: We collected 261 clinically suspected Chinese CADASIL patients from three hospitals located in different regions of China. Sanger sequencing is performed to screen the exons 2 to 24 of NOTCH3 gene. Clinical and genetic data were retrospectively studied. Haplotype analyses were performed in patients carrying p.Arg544Cys and p.Arg607Cys, respectively. RESULTS: A total of 214 patients were finally genetically diagnosed as CADASIL, with 45 known NOTCH3 mutations and a novel c.1817G>T mutation. We found that patients carrying p.Arg607Cys or p.Arg544Cys mutation located in exon 11 occupied nearly 35% in our mutation spectrum. In retrospectively study of clinical data, we found a higher number of patients having cognitive impairment and a lower number of patients having migraine with aura. Furthermore, we identified that patients carrying mutations in exon 11 seemed to experience a later disease onset (p=6.8×10-5 ). Additionally, a common haplotype was found in patients from eastern China carrying p.Arg607Cys, and the patients from Fujian carrying p.Arg544Cys shared the same haplotype with patients from Taiwan carrying p.Arg544Cys. CONCLUSIONS: These findings broaden the mutational and clinical spectrum of CADASIL and provide additional evidences for the existence of founder effect in CADASIL patients.
AIM: To characterize clinical features and mutation spectrum in Chinese patients with CADASIL. METHODS: We collected 261 clinically suspected Chinese CADASIL patients from three hospitals located in different regions of China. Sanger sequencing is performed to screen the exons 2 to 24 of NOTCH3 gene. Clinical and genetic data were retrospectively studied. Haplotype analyses were performed in patients carrying p.Arg544Cys and p.Arg607Cys, respectively. RESULTS: A total of 214 patients were finally genetically diagnosed as CADASIL, with 45 known NOTCH3 mutations and a novel c.1817G>T mutation. We found that patients carrying p.Arg607Cys or p.Arg544Cys mutation located in exon 11 occupied nearly 35% in our mutation spectrum. In retrospectively study of clinical data, we found a higher number of patients having cognitive impairment and a lower number of patients having migraine with aura. Furthermore, we identified that patients carrying mutations in exon 11 seemed to experience a later disease onset (p=6.8×10-5 ). Additionally, a common haplotype was found in patients from eastern China carrying p.Arg607Cys, and the patients from Fujian carrying p.Arg544Cys shared the same haplotype with patients from Taiwan carrying p.Arg544Cys. CONCLUSIONS: These findings broaden the mutational and clinical spectrum of CADASIL and provide additional evidences for the existence of founder effect in CADASIL patients.
Authors: M T Dotti; A Federico; R Mazzei; S Bianchi; O Scali; F L Conforti; T Sprovieri; D Guidetti; U Aguglia; D Consoli; L Pantoni; C Sarti; D Inzitari; A Quattrone Journal: J Neurol Neurosurg Psychiatry Date: 2005-05 Impact factor: 10.154
Authors: Nils Peters; Christian Opherk; Simone Zacherle; Anja Capell; Petra Gempel; Martin Dichgans Journal: Exp Cell Res Date: 2004-10-01 Impact factor: 3.905
Authors: S Reyes; A Viswanathan; O Godin; C Dufouil; S Benisty; K Hernandez; A Kurtz; E Jouvent; M O'Sullivan; V Czernecki; M G Bousser; M Dichgans; H Chabriat Journal: Neurology Date: 2009-03-10 Impact factor: 9.910
Authors: Kati Mykkänen; Marja-Liisa Savontaus; Vesa Juvonen; Pertti Sistonen; Seppo Tuisku; Susanna Tuominen; Maila Penttinen; Johan Lundkvist; Matti Viitanen; Hannu Kalimo; Minna Pöyhönen Journal: Eur J Hum Genet Date: 2004-10 Impact factor: 4.246